Picture loading failed.

Pre-Made Istiratumab biosimilar, Bispecific Mixed mAb and scFv, Anti-IGF1R;ERBB3/Erbb-3 Antibody: Anti-IGFR/CD221/IGFIR/JTK13;FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-c-erbB3/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-282-1mg 1mg Inquiry
GMP-Bios-ab-282-10mg 10mg Inquiry
GMP-Bios-ab-282-100mg 100mg Inquiry
GMP-Bios-ab-282-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Istiratumab biosimilar, Bispecific Mixed mAb and scFv, Anti-IGF1R;ERBB3/Erbb-3 Antibody: Anti-IGFR/CD221/IGFIR/JTK13;FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-c-erbB3/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
INN Name Istiratumab
TargetIGF1R;Erbb-3
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2017
Year Recommended2018
CompaniesAdimab;Merrimack Pharmaceuticals
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedOvarian cancer;Pancreatic cancer;Solid tumours
Development Techna